Medical/Pharmaceuticals
RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China
YANTAI, China, May 27, 2025 /PRNewswire/ -- On May 27, RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Products Administration (NMPA) for the treatment of adult patients with anti-acetylcholine recepto...
2025-05-27 16:30
2955
Alma Unveils Alma IQ at Eighth Global Alma Academy in Dubrovnik
The next-generation skin analysis platform, set to redefine the aesthetic
consultation experience
CAESAREA, Israel, May 27, 2025 /PRNewswire/ -- Alma
2025-05-27 07:00
2765
May 19: World Inflammatory Bowel Disease Day | Healthy Gut, Happy Life
SHENZHEN, China, May 26, 2025 /PRNewswire/ -- May 19 is designated as World Inflammatory Bowel Disease (IBD) Day, aimed at raising public awareness of IBD patients and improving their quality of life and medical care. The European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA),...
2025-05-26 21:24
4755
Esaote: The new MyLab™Heron ultrasound scanner for veterinary physicians had its world premiere at the SCIVAC Rimini 2025 Congress
GENOA, Italy, May 26, 2025 /PRNewswire/ -- Esaote, a leading company in the field of medical diagnostic imaging, has presented the world premiere of the new MyLab™Heronultrasound system at the Congress organized in Rimini from May 23 to 25 Mayby SCIVAC, the largest Veterinary Scientific Society in...
2025-05-26 18:00
3268
Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC
SHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the Chi...
2025-05-26 12:15
7190
Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)
SAN FRANCISCO and SUZHOU, China, May 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic...
2025-05-26 08:00
5174
EDAN Highlights Commitment to Global Health at GHF 2025 Satellite Symposium, a Side Event of the World Health Assembly
GENEVA, May 25, 2025 /PRNewswire/ -- Edan Instruments, Inc.
2025-05-25 21:41
6930
Mindray Debuts Next-Generation BeneVision V Series Patient Monitoring System at Euroanaesthesia 2025
SHENZHEN, China, May 25, 2025 /PRNewswire/ -- Mindray
2025-05-25 19:00
4649
Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting
* Preliminary efficacy analysis from the elacestrant plus everolimus and ribociclib cohorts of the ELEVATE study, along with updated safety data from additional cohorts of elacestrant plus targeted therapy combination arms, will be presented. * These data highlight elacestrant's potential ro...
2025-05-23 18:07
5435
Six Abstracts of Kelun-Biotech's Clinical Studies Published at the 2025 ASCO Annual Meeting
CHENGDU, China, May 23, 2025 /PRNewswire/ -- The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, the "Company") will present results from six cl...
2025-05-23 17:24
5828
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure1-3 NICE's recommendation is based on clinically meaningful results from the phase-III PROTECT trial4 ST. GALLEN, Switzerland, May 23, 2025 /PRNewswi...
2025-05-23 16:16
5244
ADVANCING ENDOSCOPIC EXCELLENCE
Pantai Hospital Kuala Lumpur Reaches 50 POEM Cases, Leading the Way in Minimally Invasive, Incisionless Treatment KUALA LUMPUR, Malaysia, May 23, 2025 /PRNewswire/ -- Pantai Hospital Kuala Lumpur (PHKL) proudly celebrates a major milestone in its endoscopic journey, having successfully performe...
2025-05-23 14:28
2695
Antengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025
* ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), achieved an overall response rate (ORR) of 36.4% and disease control rate (DCR) of 100% in checkpoint inhibitor (CPI)-resistant melanoma patients in the ongoing STAMINA-01 t...
2025-05-23 12:31
5551
Everest Medicines Announces NEFECON® Inclusion in China's Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)
SHANGHAI, May 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics,announced that NEFECON® has been included in the "Clin...
2025-05-23 11:39
3549
MindHYVE.ai™ and Islamabad Diagnostic Centre Forge Strategic Alliance to Launch AGI-Powered Diagnostic Intelligence Across Pakistan
ISLAMABAD, May 23, 2025 /PRNewswire/ -- In a groundbreaking move to elevate clinical diagnostics nationwide, MindHYVE.ai™, a U.S.-based pioneer in orchestrated agentic AI and swarm-intelligent systems, has signed a formal Memorandum of Understanding (MoU) with Islamabad Diagnostic Centre (IDC). T...
2025-05-23 09:18
2958
Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-38, an Novel Epigenetic Immune Activator, at the 2025 ASCO Annual Meeting
TAIPEI, May 23, 2025 /PRNewswire/ -- GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-38, an novel epigenetic immune activator for cancer immunotherapy. GNTbm-38 was presented as posters at the 2025 American Association of Clinical Oncology (ASCO) Annual Meeting, which ...
2025-05-23 08:00
3182
Cellenkos Inc. and King Faisal Specialist Hospital & Research Centre, Sign Strategic MOU to Advance T Regulatory Cell Therapies for Unmet Diseases
* KFSHRC to lead Clinical Trials Targeting Aplastic Anemia and Graft vs. Host Disease * Cellenkos to Support Local Cell and Gene Therapy Manufacturing at KFSHRC RIYADH, Saudi Arabia and HOUSTON, May 22, 2025 /PRNewswire/ -- King Faisal Specialist Hospital & Research Centre (KFSHRC) and Cellen...
2025-05-22 23:47
2696
Pictor Establishes U.S. Headquarters and Scales Operations, Revolutionizing Proteomics Testing Amid Regulatory Shift
CARLSBAD, Calif., May 22, 2025 /PRNewswire/ -- Pictor, a global leader in multiplex proteomics solutions, is excited to announce the establishment of its U.S. headquarters in Carlsbad, California, marking a significant milestone in its strategic growth and commitment to advancing cutting-edge sol...
2025-05-22 21:42
2936
EdgeCap-backed Comac Medical Group Expands with Acquisition of ILIFE Consulting, a French Early-phase Specialty CRO
Strategic acquisition marks significant step to establish pan-European footprint and deepens expertise in oncology and early-phase biotech clinical trials. LONDON, May 22, 2025 /PRNewswire/ -- Comac Medical Group ("Group"), based in the UK and backed by EdgeCap Partners, announced today the ac...
2025-05-22 20:20
3112
AXA Study: Over 60% of Hong Kong workers encounter elevated stress levels exceeding global average
Younger generation confronts critical mind health challenges, necessitating enhanced workplace support HONG KONG, May 22, 2025 /PRNewswire/ -- Work-related factors exert a greater influence on the mind health of Hong Kong's workforce compared to the global average, according to the latest finding...
2025-05-22 16:55
4850
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 281 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 267 media titles]
2026-09-30 10:50
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 267 media titles]
2026-10-01 10:00
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
23044
